InMed Pharmaceuticals Inc. has 5 Schedule 13D or 13G filings on record since 2026-01-20. 4 holders' latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 24.1% | 800,000 | SCHEDULE 13G, 2026-06-05 | 2026-05-31 |
| Vivo Opportunity Fund Holdings, L.P. | 21.7% | 718,444 | SCHEDULE 13D, 2026-06-10 | 2026-05-19 |
| Sabby Management, LLC | 9.9% | 280,138 | SCHEDULE 13G, 2026-01-20 | 2025-12-31 |
| Squadron Master Fund LP | 9.8% | 325,000 | SCHEDULE 13G, 2026-05-27 | 2026-05-19 |
| Ikarian Capital, LLC | 4.2% | 137,634 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
Purpose of Transaction (Item 4)
Vivo Opportunity Fund Holdings, L.P.
On May 19, 2026, the Issuer, Indigo Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Issuer (the "First Merger Sub"), Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Issuer (the "Second Merger Sub" and, together with First Merger Sub, the "Merger Subs"), and Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, (i) the First Merger Sub will merge with and into Mentari, with Mentari surviving the merger as a wholly owned subsidiary of the Company (the "First Merger"), and (ii) immediately following the First Merger and as part of the same overall transaction as the First Merger, Mentari will merge with and into the Second Merger Sub, with the Second Merger Sub surviving such merger (the "Second Merger" and, together with the First Merger, the "Merger"). Subject to the terms and conditions of the Merger Agreement, at the effective time of the First Merger (the "First Effective Time"), each share of Mentari capital stock outstanding immediately prior to the First Effective Time will be converted into the right to receive a number of the Issuer's common shares (the "Common Shares") equal to the exchange ratio determined under the Merger Agreement (the "Exchange …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-10; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-20 | Sabby Management, LLC | 9.9% | SCHEDULE 13G |
| 2026-05-27 | Squadron Master Fund LP | 9.8% | SCHEDULE 13G |
| 2026-06-05 | ADAR1 Capital Management, LLC | 24.1% | SCHEDULE 13G |
| 2026-06-10 | Vivo Opportunity Fund Holdings, L.P. | 21.7% | SCHEDULE 13D |
| 2026-08-14 | Ikarian Capital, LLC | 4.2% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for InMed Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.